Concepts (128)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cytarabine | 5 | 2012 | 1973 | 0.930 |
Why?
|
| Cytosine | 3 | 2012 | 141 | 0.810 |
Why?
|
| Arabinonucleosides | 2 | 2012 | 437 | 0.690 |
Why?
|
| DNA Breaks, Double-Stranded | 2 | 2012 | 316 | 0.680 |
Why?
|
| G2 Phase | 3 | 2008 | 206 | 0.630 |
Why?
|
| Prodrugs | 2 | 2012 | 217 | 0.470 |
Why?
|
| DNA-Activated Protein Kinase | 2 | 2011 | 76 | 0.400 |
Why?
|
| Recombination, Genetic | 1 | 2010 | 613 | 0.310 |
Why?
|
| Phenanthrenes | 3 | 2011 | 42 | 0.290 |
Why?
|
| DNA Repair | 2 | 2012 | 1872 | 0.290 |
Why?
|
| DNA Damage | 4 | 2012 | 1954 | 0.280 |
Why?
|
| DNA Replication | 1 | 2010 | 744 | 0.270 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2012 | 1299 | 0.270 |
Why?
|
| Cell Cycle Proteins | 3 | 2011 | 2045 | 0.260 |
Why?
|
| Cricetulus | 3 | 2012 | 205 | 0.220 |
Why?
|
| CHO Cells | 3 | 2012 | 311 | 0.210 |
Why?
|
| Cricetinae | 3 | 2012 | 706 | 0.200 |
Why?
|
| Naltrexone | 1 | 2001 | 87 | 0.190 |
Why?
|
| Narcotic Antagonists | 1 | 2001 | 129 | 0.190 |
Why?
|
| Ubiquinone | 1 | 1999 | 37 | 0.180 |
Why?
|
| Benzoquinones | 1 | 1999 | 108 | 0.170 |
Why?
|
| Maze Learning | 1 | 1999 | 132 | 0.170 |
Why?
|
| Morphine | 1 | 2001 | 308 | 0.170 |
Why?
|
| Pyrazines | 1 | 1999 | 495 | 0.140 |
Why?
|
| Hematologic Neoplasms | 1 | 2005 | 1870 | 0.120 |
Why?
|
| Contact Lenses, Hydrophilic | 1 | 2013 | 15 | 0.120 |
Why?
|
| DNA Topoisomerases, Type II | 2 | 2011 | 116 | 0.110 |
Why?
|
| DNA-Binding Proteins | 3 | 2012 | 4821 | 0.110 |
Why?
|
| Hydrogels | 1 | 2013 | 123 | 0.110 |
Why?
|
| Phospholipids | 1 | 2013 | 177 | 0.110 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2012 | 289 | 0.100 |
Why?
|
| Cell Line, Tumor | 6 | 2011 | 14551 | 0.100 |
Why?
|
| Topoisomerase Inhibitors | 1 | 2011 | 6 | 0.100 |
Why?
|
| Homologous Recombination | 1 | 2012 | 185 | 0.100 |
Why?
|
| Ataxia Telangiectasia | 1 | 2011 | 62 | 0.100 |
Why?
|
| Sister Chromatid Exchange | 1 | 2010 | 45 | 0.090 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2012 | 503 | 0.090 |
Why?
|
| DNA, Single-Stranded | 1 | 2010 | 106 | 0.090 |
Why?
|
| Cholesterol | 1 | 2013 | 658 | 0.090 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2011 | 430 | 0.090 |
Why?
|
| HCT116 Cells | 1 | 2010 | 348 | 0.090 |
Why?
|
| Prophase | 1 | 2009 | 7 | 0.090 |
Why?
|
| HeLa Cells | 2 | 2010 | 1643 | 0.090 |
Why?
|
| Staurosporine | 2 | 2007 | 143 | 0.080 |
Why?
|
| Drug Resistance | 1 | 2010 | 587 | 0.080 |
Why?
|
| Phenanthridines | 1 | 2007 | 10 | 0.080 |
Why?
|
| Animals | 7 | 2012 | 59536 | 0.080 |
Why?
|
| DNA Repair Enzymes | 1 | 2009 | 237 | 0.080 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2007 | 58 | 0.070 |
Why?
|
| Cell Survival | 2 | 2011 | 3045 | 0.070 |
Why?
|
| Antigens, Neoplasm | 2 | 2011 | 1506 | 0.070 |
Why?
|
| Deoxycytidine | 1 | 2012 | 1353 | 0.070 |
Why?
|
| Cell Cycle | 1 | 2012 | 2084 | 0.070 |
Why?
|
| Neoplasms | 1 | 2012 | 15193 | 0.070 |
Why?
|
| Cell Line | 2 | 2010 | 5114 | 0.060 |
Why?
|
| CDC2 Protein Kinase | 1 | 2005 | 176 | 0.060 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2005 | 174 | 0.060 |
Why?
|
| Artifacts | 1 | 2007 | 532 | 0.060 |
Why?
|
| Clinical Trials as Topic | 2 | 2012 | 3719 | 0.060 |
Why?
|
| Drug Interactions | 1 | 2005 | 553 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 2594 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2011 | 1823 | 0.060 |
Why?
|
| Mitosis | 1 | 2005 | 615 | 0.060 |
Why?
|
| Chromosome Aberrations | 2 | 2007 | 1960 | 0.050 |
Why?
|
| Polyglycolic Acid | 1 | 2001 | 34 | 0.050 |
Why?
|
| Phantoms, Imaging | 1 | 2007 | 1271 | 0.050 |
Why?
|
| Protein Kinases | 1 | 2005 | 874 | 0.050 |
Why?
|
| Delayed-Action Preparations | 1 | 2001 | 208 | 0.050 |
Why?
|
| Microspheres | 1 | 2001 | 210 | 0.050 |
Why?
|
| Analgesia | 1 | 2001 | 94 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 3154 | 0.040 |
Why?
|
| Polymers | 1 | 2001 | 223 | 0.040 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2010 | 6915 | 0.040 |
Why?
|
| Lactic Acid | 1 | 2001 | 305 | 0.040 |
Why?
|
| Humans | 11 | 2013 | 261506 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2009 | 3343 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 1999 | 324 | 0.040 |
Why?
|
| alpha-Galactosidase | 1 | 1995 | 14 | 0.030 |
Why?
|
| X Chromosome | 1 | 1995 | 339 | 0.030 |
Why?
|
| Anticoagulants | 1 | 1999 | 787 | 0.030 |
Why?
|
| 1-Propanol | 1 | 2013 | 2 | 0.030 |
Why?
|
| Adsorption | 1 | 2013 | 46 | 0.030 |
Why?
|
| Contact Lens Solutions | 1 | 2013 | 7 | 0.030 |
Why?
|
| Lubricant Eye Drops | 1 | 2013 | 11 | 0.030 |
Why?
|
| Silicones | 1 | 2013 | 54 | 0.030 |
Why?
|
| Materials Testing | 1 | 2013 | 116 | 0.030 |
Why?
|
| Antineoplastic Agents | 4 | 2011 | 14289 | 0.030 |
Why?
|
| Biocompatible Materials | 1 | 2013 | 202 | 0.030 |
Why?
|
| Mice | 3 | 2008 | 34495 | 0.030 |
Why?
|
| Young Adult | 1 | 2010 | 21445 | 0.020 |
Why?
|
| Apoptosis | 1 | 2005 | 7591 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 29902 | 0.020 |
Why?
|
| Adolescent | 1 | 2010 | 31252 | 0.020 |
Why?
|
| Nocodazole | 1 | 2009 | 24 | 0.020 |
Why?
|
| Lipids | 1 | 2013 | 644 | 0.020 |
Why?
|
| Female | 3 | 2010 | 141928 | 0.020 |
Why?
|
| Tubulin Modulators | 1 | 2009 | 65 | 0.020 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2009 | 189 | 0.020 |
Why?
|
| Spindle Apparatus | 1 | 2009 | 93 | 0.020 |
Why?
|
| Centrosome | 1 | 2009 | 95 | 0.020 |
Why?
|
| Exodeoxyribonucleases | 1 | 2009 | 104 | 0.020 |
Why?
|
| Dioxolanes | 1 | 2008 | 41 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1995 | 1756 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2005 | 11965 | 0.020 |
Why?
|
| Scattering, Radiation | 1 | 2007 | 316 | 0.020 |
Why?
|
| Male | 2 | 2010 | 123000 | 0.020 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2007 | 202 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2007 | 566 | 0.020 |
Why?
|
| Aged | 1 | 2010 | 70117 | 0.020 |
Why?
|
| Adult | 1 | 2010 | 77950 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2009 | 1555 | 0.010 |
Why?
|
| Middle Aged | 1 | 2010 | 86204 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 6009 | 0.010 |
Why?
|
| Breast | 1 | 2007 | 1344 | 0.010 |
Why?
|
| Histones | 1 | 2007 | 1466 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 1879 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2007 | 4804 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 4938 | 0.010 |
Why?
|
| Algorithms | 1 | 2007 | 3890 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2008 | 3552 | 0.010 |
Why?
|
| Cosmids | 1 | 1995 | 40 | 0.010 |
Why?
|
| Fabry Disease | 1 | 1995 | 15 | 0.010 |
Why?
|
| Gene Library | 1 | 1995 | 294 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1995 | 362 | 0.010 |
Why?
|
| Introns | 1 | 1995 | 432 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1995 | 4233 | 0.010 |
Why?
|
| Base Sequence | 1 | 1995 | 4917 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1995 | 6089 | 0.000 |
Why?
|